SEC Company Response from REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589) (REGN) — Jun 12, 2014
REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589)
Date: June 12, 2014 · CIK: 0000872589 · Accession: 0001532176-14-000024
AI Filing Summary & Sentiment
File numbers found in text: 000-19034
Referenced dates: April 30, 2014
Letter
Via EDGAR Division of Corporation Finance Regeneron Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed February 13, 2014 File No. 000-19034
Dear Mr. Rosenberg:
Regeneron Pharmaceuticals, Inc. (the “Company”) acknowledges receipt of oral comments provided by the staff of the Securities and Exchange Commission on June 3, 2014, with respect to the above-referenced Form 10-K. The Company subsequently corresponded with Scott Wuenschell on June 9, 2014, who kindly granted the Company’s request for a five business day extension. Accordingly, the Company plans to expand its explanations to supplement its initial responses in its letter dated April 30, 2014, on or before June 24, 2014.
If you have any questions regarding the foregoing, please contact me at (914) 847-7270.
Very truly yours,
REGENERON PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm Comment Letter - June 2014 Request for Response Extension Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 Phone 914 847 7000 www.regeneron.com June 12, 2014 Via EDGAR Mr. Jim B. Rosenberg Senior Assistant Chief Accountant U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Regeneron Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2013 Filed February 13, 2014 File No. 000-19034 Dear Mr. Rosenberg: Regeneron Pharmaceuticals, Inc. (the “Company”) acknowledges receipt of oral comments provided by the staff of the Securities and Exchange Commission on June 3, 2014, with respect to the above-referenced Form 10-K. The Company subsequently corresponded with Scott Wuenschell on June 9, 2014, who kindly granted the Company’s request for a five business day extension. Accordingly, the Company plans to expand its explanations to supplement its initial responses in its letter dated April 30, 2014, on or before June 24, 2014. If you have any questions regarding the foregoing, please contact me at (914) 847-7270. Very truly yours, REGENERON PHARMACEUTICALS, INC. /s/ Robert E. Landry Robert E. Landry Senior Vice President, Finance and Chief Financial Officer cc: Securities and Exchange Commission Scott Wuenschell Joel Parker